For treatment purposes, breast cancer is generally divided into three clinical subtypes: HR-positive/HER2-negative (HR + /HER2-), HER2-positive (HER2 +), and TNBC [HR-negative (HR-), HER2-] [4, 5]. This evidence concerns the gene ERBB2 and breast carcinoma.